ANEB · Anebulo Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.16M | $810.0K | $1.22M | $638.3K | $1.31M | $1.06M | $748.3K | $1.27M | $1.87M | $1.09M |
| SG&A | $1.46M | $1.45M | $1.37M | $1.25M | $1.10M | $1.70M | $915.9K | $1.27M | $1.94M | $1.77M |
| Total Operating Expenses | $2.62M | $2.26M | $2.59M | $1.89M | $2.41M | $2.76M | $1.66M | $2.54M | $3.81M | $2.86M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($2.62M) | ($2.26M) | ($2.59M) | ($1.89M) | ($2.41M) | ($2.76M) | ($1.66M) | ($2.54M) | ($3.81M) | ($2.86M) |
| Interest Expense | $17.0K | $100.0K | $31.8K | $100.0K | $59.7K | $31.8K | $59.7K | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.00M) | ($2.16M) | ($2.46M) | ($1.68M) | ($2.20M) | ($2.72M) | ($1.65M) | ($2.48M) | ($3.83M) | ($2.80M) |
| EPS - Basic | ($0.05) | ($0.05) | ($0.09) | ($0.04) | ($0.08) | ($0.11) | ($0.06) | ($0.10) | ($0.05) | ($0.11) |
| EPS - Diluted | ($0.05) | ($0.05) | ($0.09) | ($0.04) | ($0.08) | ($0.15) | ($0.06) | ($0.11) | - | - |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.04M | $10.35M | $11.63M | $13.28M | $1.40M | $3.09M | $5.15M | $11.25M | $11.25M | $14.16M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $554.9K | $607.5K | $224.2K | $427.6K | $252.1K | $156.4K | $384.9K | $565.9K | $534.5K | $570.9K |
| Current Assets | $9.27M | $10.54M | $11.96M | $13.81M | $1.96M | $3.51M | $5.37M | - | - | - |
| Total Assets | $9.42M | $10.70M | $12.15M | $14.01M | $2.47M | $4.07M | $6.00M | $9.05M | $11.67M | $14.43M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.49M | $963.8K | $487.7K | $546.0K | $569.2K | $260.6K | $1.01M | $716.6K | $1.07M | $1.49M |
| Stockholders' Equity | $7.94M | $9.74M | $11.66M | $13.46M | $1.90M | $3.81M | $4.99M | $8.33M | $10.60M | $12.94M |
| Retained Earnings | ($78.05M) | ($76.05M) | ($73.89M) | ($71.74M) | ($67.60M) | ($65.40M) | ($64.05M) | ($59.68M) | ($57.20M) | ($54.71M) |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($1.27M) | - | - | ($1.69M) | - | - | ($2.73M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -21.2% | -20.2% | -20.3% | -12.0% | -89.2% | -66.7% | -27.6% | -27.4% | -32.8% | -19.4% |
| Return on equity | -25.2% | -22.2% | -21.1% | -12.5% | -115.9% | -71.3% | -33.2% | -29.8% | -36.1% | -21.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | - | - | - | - | - | - | - | - | - | - |
| Quick ratio | - | - | - | - | - | - | - | - | - | - |
| Cash ratio | - | - | - | - | - | - | - | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -154.1x | -22.6x | -81.3x | -18.9x | -40.4x | -86.7x | -27.9x | - | - | - |
| Equity multiplier | 1.19 | 1.10 | 1.04 | 1.04 | 1.30 | 1.07 | 1.20 | 1.09 | 1.10 | 1.12 |
| Liabilities / Assets | 0.16 | 0.09 | 0.04 | 0.04 | 0.23 | 0.06 | 0.17 | 0.08 | 0.09 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 5.2x | 10.5x | 3.4x | 4.0x | 26.4x | 18.5x | 14.9x | 8.6x | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -1.2% | 6.3% | 6.2% | -13.7% | 5.2% | 27.6% | 41.9% | 2.6% | -1074.8% | -418.7% |
| Net income growth (YoY) | 18.8% | 1.9% | 9.4% | -1.4% | 11.3% | 29.0% | 40.9% | 5.0% | -256.7% | -49.1% |
| EPS growth (YoY) | 44.4% | 37.5% | 40.0% | 33.3% | 27.3% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -31.9% | 412.8% | 205.8% | 170.0% | -77.2% | -64.0% | -61.5% | -56.4% | -29.6% | -24.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Anebulo Pharmaceuticals against the 5 most active filers in the same SIC group.